Biomarker NTRK Coverage from Every Angle

Alexander Drilon, MD, on NTRK Fusion Basics: An Expert Overview

Posted: Sunday, August 1, 2021

Alexander E. Drilon, MD, of Memorial Sloan Kettering Cancer Center, reviews the current landscape of NTRK fusions, drivers of multiple cancers in children and adults, and the effective first-generation targeted therapies (larotrectinib and entrectinib) approved by the U. S. Food and Drug Administration to treat them.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.